Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. FUJIFILM Holdings Corporation
  6. News
  7. Summary
    4901   JP3814000000

FUJIFILM HOLDINGS CORPORATION

(4901)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Fujifilm : Showcases Comprehensive Portfolio of Enterprise Imaging Solutions at the Virtual SIIM 2021 Conference

05/24/2021 | 08:45am EDT

The content on this page is intended to healthcare professionals and equivalents.

FUJIFILM Medical Systems U.S.A., Inc. announced it will showcase its portfolio of Synapse Enterprise Imaging solutions at the 2021 Society for Imaging Informatics in Medicine (SIIM) Conference taking place May 24- 27.

'SIIM is the premier platform to engage with the global radiology informatics community, and as connectivity is the nature of our business, we look forward to collaborating virtually with this critical part of the healthcare community,' said Bill Lacy, Vice President of Medical Informatics at FUJIFILM Medical Systems, U.S.A., Inc. 'We're excited to share our innovative solutions to empower the real-time, cross-departmental image access and collaboration that healthcare requires now more than ever.'

During the virtual SIIM 2021 conference, Fujifilm will showcase its portfolio of Synapse Enterprise Imaging solutions, including:

Synapse 7x, Fujifilm's next-generation PACS image visualization platform, which unites radiology, cardiology, enterprise imaging, advanced visualization and AI through a single, zero-footprint PACS viewer.

Fujifilm's open AI-enabled platform REiLI brings cutting-edge AI insights directly within the workflow of Synapse PACS users, helping to enhance diagnostic accuracy, streamline efficiency, and seamlessly support those diagnostic interpretations.

2020 & 2021's Best-in-KLAS Synapse VNA from the TeraMedica Division of Fujifilm. Storing more than 40 billion imaging objects from more than 1,500 facilities across six continents, Fujifilm's patented VNA technology integrates more specialties, more devices, and more data than any other VNA on the market to unify every form of digital content associated with the patient record

Synapse EIS, with Synapse radiology information systems (RIS) as its centerpiece, provides one of the most comprehensive (RIS and informatics workflow solutions on the market., It extends the robust technology capabilities to deliver extensive workflow management to support professionals in radiology and across the enterprise, enhancing staff productivity and the patient experience.

Synapse Cloud Services, which provides a scalable and secure environment to host and manage the Synapse Enterprise Imaging portfolio. Critical-access hospitals, imaging centers, and teleradiology providers can take advantage of Fujifilm's cloud-based infrastructure and interoperable software to maximize efficiency and cost savings.

Visit Fujifilm's SIIM 2021 landing page for more information and to request a demonstration at booth 3837 later this summer at HIMSS 2021.

About Fujifilm

FUJIFILM Medical Systems U.S.A., Inc. is a leading provider of innovative diagnostic imaging products and medical informatics solutions that meet and exceed the evolving needs of healthcare facilities today and into the future. It's ever expanding medical imaging solutions span digital radiography (DR), detectors, portables and suites, mammography systems with digital breast tomosynthesis, computed tomography solutions for oncology and radiology applications, technologically advanced flexible and surgical endoscopy and fluoroscopy solutions. Fujifilm enables interoperability through its Systems Integration offering as well as its comprehensive, AI-supported Synapse Enterprise Imaging portfolio, which includes the TeraMedica Division of Fujifilm. Fujifilm's in vitro diagnostics (IVD) portfolio includes clinical lab reagents, and biomarkers to assess the risk for the development of hepatocellular carcinoma in patients with chronic liver disease. FUJIFILM Medical Systems U.S.A., Inc. is headquartered in Lexington, Massachusetts. For more information please visit www.fujifilmhealthcare.com.

FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, highly functional materials, document solutions and imaging products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2021, the company had global revenues of $21 billion, at an exchange rate of 106 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.

Contact:

Danielle Brown

Fujifilm

914-574-3273

Danielle.Brown@fujifilm.com

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about FUJIFILM HOLDINGS CORPORATION
01:30pFUJIFILM : US Radiology Specialists Selects Fujifilm's Synapse Enterprise Inform..
AQ
07/19Charter Hall Long Wale Reit Enters into A Lease for Building C, 56 Edmondston..
CI
07/14FUJIFILM : Launches Virtual Hospital to Showcase that it's Comprehensive Healthc..
AQ
07/12FUJIFILM : finds new niches, record profits amid pandemic
AQ
07/09New Fujifilm CEO focuses on drug ingredients unit after Avigan stumbles
RE
07/01FUJIFILM : closing South Carolina plants; 400 to lose jobs
AQ
06/30FUJIFILM : Business Innovation Announces Management Changesá(FUJIFILM Business I..
PU
06/24FUJIFILM : Expands Integrated Inkjet Solutions Business
AQ
06/24FUJIFILM : releases new features for its FUJIFILM 42K Printbar System; a configu..
AQ
06/24FUJIFILM : Enters Flexible Packaging Market with Launch of New Digital Inkjet Wa..
AQ
More news
Financials
Sales 2022 2 457 B 22 274 M 22 274 M
Net income 2022 148 B 1 344 M 1 344 M
Net Debt 2022 232 B 2 106 M 2 106 M
P/E ratio 2022 21,8x
Yield 2022 1,27%
Capitalization 3 222 B 29 211 M 29 208 M
EV / Sales 2022 1,41x
EV / Sales 2023 1,35x
Nbr of Employees 73 275
Free-Float 73,9%
Chart FUJIFILM HOLDINGS CORPORATION
Duration : Period :
FUJIFILM Holdings Corporation Technical Analysis Chart | 4901 | JP3814000000 | MarketScreener
Technical analysis trends FUJIFILM HOLDINGS CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 8 059,00 JPY
Average target price 8 471,43 JPY
Spread / Average Target 5,12%
EPS Revisions
Managers and Directors
Shigetaka Komori Chairman & Group Chief Executive Officer
Kenji Sukeno President, Group COO & Representative Director
Takashi Iwasaki Director & Chief Technology Officer
Kunitaro Kitamura Independent Outside Director
Tatsuo Kawada Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
FUJIFILM HOLDINGS CORPORATION48.20%29 378
ABBOTT LABORATORIES10.33%200 283
MEDTRONIC PLC9.73%168 081
BECTON, DICKINSON AND COMPANY0.34%70 145
HOYA CORPORATION5.96%50 251
ALIGN TECHNOLOGY, INC.19.44%48 667